Can Rosuvastatin (Rosuvas) Cause Gastritis?
Rosuvastatin does not directly cause gastritis, but gastrointestinal side effects including dyspepsia and nausea can occur, though these are not more common than placebo in controlled trials. 1
Evidence from Guidelines and Drug Labels
The most authoritative evidence comes from the 2013 Canadian Working Group Consensus on statin adverse effects, which specifically addresses gastrointestinal symptoms with statins. According to this guideline, while gastrointestinal side effects such as flatulence, dyspepsia, nausea, and abdominal discomfort are reported by patients taking statins, meta-analyses of clinical trials demonstrate that the incidence of these adverse effects is not greater in statin-treated patients compared with placebo-treated control subjects. 1
The FDA drug label for rosuvastatin lists the most common side effects as headache, nausea, muscle aches and pains, weakness, and constipation—but notably does not list gastritis as a recognized adverse effect. 2 The label does mention that antacids containing aluminum and magnesium hydroxide should be taken at least 2 hours after rosuvastatin, suggesting awareness of gastrointestinal considerations but not gastritis per se. 2
Clinical Context and Risk Factors
When gastrointestinal symptoms do occur with statins, the Canadian guideline identified specific risk factors:
- Female sex
- East Indian race
- Alcohol consumption
- Higher statin doses
- Secondary dyslipidemia
- Diabetes mellitus
- Concurrent β-blocker use 1
In one cross-sectional study cited in the guideline, 4.8% of patients discontinued statin therapy due to gastrointestinal side effects, with flatulence being the most prevalent complaint. 1
Emerging Research Evidence
Interestingly, recent research suggests rosuvastatin may actually have gastroprotective properties rather than causing gastritis. A 2024 animal study demonstrated that rosuvastatin protected against ethanol-induced gastric ulceration through antioxidant and anti-inflammatory mechanisms, maintaining mucosal integrity and prostaglandin E2 levels. 3 Additionally, a 2010 study found that long-term statin therapy may actually reduce the severity of chronic gastritis. 4
Practical Clinical Considerations
In real-world studies comparing rosuvastatin to atorvastatin:
- A 2020 Indian cohort study found GERD/gastritis occurred in 4.83% of patients on rosuvastatin 40mg versus 2.18% on atorvastatin 80mg 5
- A 2025 FAERS database analysis identified gastrointestinal adverse events as one of the most common system organ classes affected by rosuvastatin-fenofibrate combination therapy 6
However, these observational findings must be interpreted cautiously, as the guideline-level evidence from controlled trials shows no increased risk versus placebo. 1
Clinical Recommendation
If a patient on rosuvastatin develops gastrointestinal symptoms:
- Consider other causes first (H. pylori, NSAIDs, alcohol, dietary factors)
- Review concomitant medications, particularly antacids and their timing
- Assess for the risk factors listed above
- Remember that true gastritis (inflammation of gastric mucosa) is not an established statin adverse effect
- If symptoms persist and other causes are excluded, consider dose reduction or switching to another statin rather than discontinuing lipid-lowering therapy entirely
The cardiovascular benefits of statin therapy in appropriate patients far outweigh the minimal gastrointestinal symptoms that occur at rates similar to placebo.